A. Jesus-Acosta

发表

Baseline Hemoglobin-A 1 c Impacts Clinical Outcomes in Patients With Pancreatic Cancer

T. Pawlik, E. Fishman, R. Hruban, 2014 .

Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy

J. Herman, Jeffrey Meyer, D. Laheru, 2022, Radiation oncology journal.

A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).

A. Maitra, V. Bolejack, P. O'dwyer, 2014 .

Efficacy of Platinum Chemotherapy Agents in the Adjuvant Setting for Adenosquamous Carcinoma of the Pancreas

J. Cameron, T. Pawlik, R. Hruban, 2013 .

An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma

E. Jaffee, J. Leal, D. V. Von Hoff, 2020, Oncotarget.

Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study

P. Ott, S. Piha-Paul, A. Hansen, 2019, Annals of Oncology.

Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships

J. Cameron, T. Pawlik, L. Wood, 2013, Journal of Radiation Oncology.

A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC).

E. Sugar, D. Laheru, Jin He, 2021 .

Preliminary Results of a Pilot Study Evaluating An Allogeneic GM-CSF Pancreatic Tumor Cell Vaccine (GVAX) and Cytoxan (Cy) With Stereotactic Body Radiation Therapy (SBRT) and Folfirinox (FFX) in Patients With Resected Pancreatic Adenocarcinoma

J. Cameron, T. Pawlik, E. Fishman, 2015 .

Pancreatic neuroendocrine tumors: Challenges in an underestimated disease.

R. Vera, A. Viúdez, F. Carvalho, 2016, Critical reviews in oncology/hematology.

Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns

E. Fishman, R. Hruban, elliot k fishman, 2015, Oncotarget.

A phase II trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in patients with metastatic pancreatic cancer.

L. Diaz, R. Donehower, D. Cosgrove, 2014 .

Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.

V. Velculescu, D. Heitjan, P. O'dwyer, 2015 .

Spotlight on Clinical Response Personalizing Cancer Treatment in the Age of Global Genomic Analyses : PALB 2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

Siân Jones, R. Hruban, J. Eshleman, 2011 .

Hemoglobin-A1c level to predict for clinical outcomes in patients with pancreatic cancer.

T. Pawlik, E. Fishman, R. Hruban, 2013 .